human yap1  (OriGene)

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: ( A )YAP1 protein is expressed in different cell types relevant to the brain, such as astrocytes (CCF-STTG1), microglia (HMC3), neuroblastoma (SH-SY5Y), and NT2 cells, as demonstrated by immunoblotting. Data are mean ± SEM ( n = 3). ( B ) Images show immunocytochemical evidence of YAP1 expression (in green) and DAPI-stained nuclei (in blue) in different cell types and human neurons. Scale: 20 µm.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques: Western Blot, Expressing, Staining

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: YAP1 protein levels are significantly downregulated in the nuclear fractions but not the cytosolic fractions of the AD brains relative to NC brains. Brain lysates were immunoblotted, and protein levels were quantified by normalizing to HDAC2 levels for nuclear fractions and to GAPDH levels for cytosolic fractions. Data are mean ± SEM ( n = 5 per group). *** p < 0.001 by t -test.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques:

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: Antibody-based multiplex microarray screening of 8000 proteins revealed alterations of specific proteins. ( A ) SH-SY5Y cells expressing YAP1-GFP. Scale, 50 µm. ( B ) YAP1-GFP expression supported by immunoblot. ( C ) Examples of glass slide luminescence. ( D ) Heatmap of control and YAP1 biomarkers in 8000 samples. The data were imported to JMP Genomics 10.2 for Hierarchical Cluster analysis.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques: Multiplex Assay, Microarray, Expressing, Western Blot, Control

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: YAP1 expression increased markers of synaptic endocytosis and ATP-dependent activity. ( A ) Gene ontology (GO) biological process over-representation analysis with 283 differentially expressed biomarkers between YAP1 and control samples. ( B ) GO cellular component over-representation analysis with 283 differentially expressed biomarkers between control and YAP1-expressing SH-SY5Y cells.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques: Expressing, Activity Assay, Control

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: ( A ) GO molecular function over-representation analysis with 283 differentially expressed biomarkers between YAP1 and control samples. ( B ) Interaction network of human YAP1 protein as analyzed by STRING.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques: Control

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: The bar graph shows GO analysis results of the increased ( A ) and decreased proteins ( B ) due to YAP1 expression using ShinyGO 0.85.1. Sets of nonredundant, significant GO enrichment terms are displayed to show the foldenrichment and the number of proteins matched to each term. The fold-enrichment values are displayed with the highest on top, and the shade of each bar reflects the number of proteins found in a given GO category.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques: Expressing

Journal: Neurology International

Article Title: YAP1 Upregulates Cytoskeleton Regulator ARHGEF1 and Tissue Regeneration Factor NEDD9 in a Multiplex Proteomic Study

doi: 10.3390/neurolint18050096

Figure Lengend Snippet: Evidence of increased levels of ( A ) NEDD9 and ( B ) ARHGEF1 inYAP1-GFP-expressing SH-SY5Y cells when compared to control cells by immunoblotting. ( C ) The LC3-16/LC3-18 ratio was also increased, indicating YAP1 activates autophagy. However, levels of ( D ) p16INK4a, a marker of senescence, were almost completely abolished. Data are mean + SEM, n = 3/group. *, p < 0.05, **, p < 0.01, ***, p < 0.001 by t -test.

Article Snippet: We cultured the immortalized human neuroblastoma cell line SH-SY5Y (cat # CRL2266, ATCC) in DMEM/F12 medium and infected only once with Lenti ORF particles, human YAP1 (mGFP-tagged) transcript variant 1 (cat # RC225864L4V, Origene, Rockville, MD, USA), and generated stable cells expressing YAP1-GFP with puromycin selection at 5.0 μg per milliliter for two weeks.

Techniques: Expressing, Control, Western Blot, Marker

Journal: bioRxiv

Article Title: The regulatory landscape of optic fissure closure in the vertebrate eye

doi: 10.64898/2026.02.11.705341

Figure Lengend Snippet: ( A-D ) Number of peaks and highest match de novo motifs identified by HOMER for each context specific category. Only motifs with a percentage of target to background ratio > 1.5 were included. ( E-H ) Histograms showing motif occurrence distribution around the centre of peaks corresponding to analysis in A-D. Lines without observable enrichment are translucent. Motif consensus sequences and their likely TF identities are shown below and heights correlate to the frequency of base occurrence. ( I ) YAP1 immunofluorescence during chicken OFC at HH30 showed highest signal (arrows) in the edges of the fusing OFM and in the fused margins. In contrast, low signal was detected in dorsal tissue. Abbreviations : RPE, retinal pigmented epithelium, NR, neural retina; POM, periocular mesenchyme.

Article Snippet: Immunofluorescence of YAP1 was performed using methods described previously , but using rabbit anti-human YAP1 antibody (D8H1X, Cell Signalling Technology) diluted 1:50 in block solution (PBS, 0.1% BSA, 0.05% Triton X-100) and incubated overnight at 4°C, and detected with Alexa-fluor 488nm goat anti-rabbit secondary antibody (1:1000 dilution; A11037, Thermo Fisher) and DAPI (1:1000 dilution; D3571, Thermo Fisher).

Techniques: Immunofluorescence

Journal: bioRxiv

Article Title: The regulatory landscape of optic fissure closure in the vertebrate eye

doi: 10.64898/2026.02.11.705341

Figure Lengend Snippet: (A) Shared sequence similarities for homeodomain motifs LHX2, VAX1, ALX1 and LHX2. ( B ) TPM plot showing expression patterns of TEAD1 , TEAD3 , TEAD4 and YAP1 from the RNA-seq analysis . (C) TPM of transcription factors expression levels from the RNA-seq data. Only values for transcription factor genes with a motif enrichment indicated by HOMER were plotted.

Article Snippet: Immunofluorescence of YAP1 was performed using methods described previously , but using rabbit anti-human YAP1 antibody (D8H1X, Cell Signalling Technology) diluted 1:50 in block solution (PBS, 0.1% BSA, 0.05% Triton X-100) and incubated overnight at 4°C, and detected with Alexa-fluor 488nm goat anti-rabbit secondary antibody (1:1000 dilution; A11037, Thermo Fisher) and DAPI (1:1000 dilution; D3571, Thermo Fisher).

Techniques: Sequencing, Expressing, RNA Sequencing

Journal: Communications Biology

Article Title: Exosomal miR-212-5p promotes tendon repair via targeting FOXO1 to activate PP1A/YAP1 signaling

doi: 10.1038/s42003-025-09210-5

Figure Lengend Snippet: A qPCR was performed to assess FOXO1 expression in TDSCs after treatment with exosomes derived from miR-212-5p -depleted ADSCs. B Western blot was conducted to evaluate FOXO1 and p-YAP1 levels after treatment with exosomes derived from miR-212-5p-depleted ADSCs. C Bioinformatics analysis using the Starbase database was performed to predict the target interaction between miR-212-5p and FOXO1 . D qPCR was used to measure miR-212-5p levels in TDSCs after transfection with miR-212-5p mimics. E Dual-luciferase reporter assay was used to assess luciferase activity after treatment with exosomes derived from miR-212-5p -depleted or miR-212-5p -overexpressing ADSCs. F RNA pull-down assay was conducted using biotin-labeled miR-212-5p to evaluate its binding interaction with FOXO 1. G qPCR was performed to assess FOXO 1 expression after transfection with shFOXO1 in ADSCs. H Western blot analysis was used to evaluate FOXO1 and p-YAP1 levels after knockdown of miR-212-5p in ADSC-Exos and simultaneous knockdown of FOXO1. Data are presented as mean ± SD, and statistical analysis was conducted using a student t-test (for D , F – G ) of one-way ANOVA followed by Tukey’s post hoc test (for A , B , E , H ). n = 3.*p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The cDNA ORF coding full sequences for YAP1 (Origene, Shanghai, China) mutant serine-to-alanine mutation at position 127 (S127A) was generated through PCR-based site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Sacramento, CA, USA) following the manufacturer ́s protocol, and was subcloned into an overexpressing vector.

Techniques: Expressing, Derivative Assay, Western Blot, Transfection, Luciferase, Reporter Assay, Activity Assay, Pull Down Assay, Labeling, Binding Assay, Knockdown

Journal: Communications Biology

Article Title: Exosomal miR-212-5p promotes tendon repair via targeting FOXO1 to activate PP1A/YAP1 signaling

doi: 10.1038/s42003-025-09210-5

Figure Lengend Snippet: A , B qPCR and Western blot were performed to analyze PP1A levels in TDSCs transfected with shNC or shFOXO1 after treatment with exosomes derived from miR-212-5p-depleted ADSCs. C The JASPAR database was used to predict FOXO1 binding sites on the PP1A promoter. D ChIP assay was conducted using a FOXO1 antibody to assess its binding to the PP1A promoter. E , F qPCR and Western blot were performed to evaluate FOXO1 expression in TDSCs after transfection with FOXO1 overexpression vectors. G Dual-luciferase reporter assay was used to investigate the impact of FOXO1 knockdown and overexpression on PP1A transcriptional activity. H qPCR was performed to assess PP1A expression following FOXO1 knockdown and overexpression in TDSCs. I qPCR was conducted to evaluate PP1A expression after transfection with shPP1A in TDSCs. J Western blot was performed to study the effects of FOXO1 and PP1A knockdown on PP1A and p-YAP1 levels. K Immunofluorescence was used to examine nuclear YAP1 levels (green) in TDSCs after FOXO1 and PP1A knockdown. Scale bar: 100 μm. Data are presented as mean ± SD, and statistical analysis was conducted using a student t-test (for D – F , I ) of one-way ANOVA followed by Tukey’s post hoc test (for A , B , G , H , J ). n = 3 **p < 0.01, ***p < 0.001.

Article Snippet: The cDNA ORF coding full sequences for YAP1 (Origene, Shanghai, China) mutant serine-to-alanine mutation at position 127 (S127A) was generated through PCR-based site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Sacramento, CA, USA) following the manufacturer ́s protocol, and was subcloned into an overexpressing vector.

Techniques: Western Blot, Transfection, Derivative Assay, Binding Assay, Expressing, Over Expression, Luciferase, Reporter Assay, Knockdown, Activity Assay, Immunofluorescence

Journal: Communications Biology

Article Title: Exosomal miR-212-5p promotes tendon repair via targeting FOXO1 to activate PP1A/YAP1 signaling

doi: 10.1038/s42003-025-09210-5

Figure Lengend Snippet: A Western blot was performed to analyze the effects of transfection with wild-type YAP1 (YAP1-WT) expression vectors or S127A mutant YAP1 expression vectors (YAP1-S127A) on YAP1 and p-YAP1 levels. B – F MTT, EdU staining, scratch assay, Transwell assay, and Western blot were used to evaluate TDSC proliferation, migration, and the expression of tenogenic differentiation markers, including TNC, TNMD, Scx, COL1A1, and GAPDH, after FOXO1 overexpression with simultaneous overexpression of the S127A mutant YAP1. Scale bar: 100 or 500 μm. G Alcian Blue staining was performed to evaluate cartilage-like matrix deposition in TDSCs. Scale bar: 100 μm. Data are presented as mean ± SD, and statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc test. n = 3. **p < 0.01, ***p < 0.001.

Article Snippet: The cDNA ORF coding full sequences for YAP1 (Origene, Shanghai, China) mutant serine-to-alanine mutation at position 127 (S127A) was generated through PCR-based site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Sacramento, CA, USA) following the manufacturer ́s protocol, and was subcloned into an overexpressing vector.

Techniques: Western Blot, Transfection, Expressing, Mutagenesis, Staining, Wound Healing Assay, Transwell Assay, Migration, Over Expression

Journal: Communications Biology

Article Title: Exosomal miR-212-5p promotes tendon repair via targeting FOXO1 to activate PP1A/YAP1 signaling

doi: 10.1038/s42003-025-09210-5

Figure Lengend Snippet: A Hematoxylin and eosin (HE) staining was performed to evaluate the arrangement of fibrous tissue in tendons from mice treated with exosomes derived from normal or miR-212-5p -depleted ADSCs. Scale bar: 50 or 20 μm. B Safranin O/Fast Green staining of tendon sections to evaluate ectopic cartilage-like matrix formation after injury in different groups of mice. Scale bar: 50 or 20 μm. C Immunohistochemistry (IHC) was used to assess the levels of TNMD, Scx, COL1A1, and SOX9 in tendon tissues from different groups of mice. Scale bar: 20 μm D , E Western blot analysis was conducted to examine the expression of tenogenic differentiation markers, including TNC, TNMD, Scx, and COL1A1, as well as PP1A, FOXO1, and p-YAP1 levels in tendon tissues from different groups of mice. F , G Biomechanical testing was performed to measure the failure load and stiffness of tendon tissues from different groups of mice. Data are presented as mean ± SD, and statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc test. n = 6. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The cDNA ORF coding full sequences for YAP1 (Origene, Shanghai, China) mutant serine-to-alanine mutation at position 127 (S127A) was generated through PCR-based site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Sacramento, CA, USA) following the manufacturer ́s protocol, and was subcloned into an overexpressing vector.

Techniques: Staining, Derivative Assay, Immunohistochemistry, Western Blot, Expressing

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: A . Increased YAP1 or TAZ in GC tumor tissues compared to normal tissues ( http://gepia.cancer-pku.cn ). B . Both YAP1 and TAZ are significantly correlated (R=0.42; P value=0). C & D . Expression of YAP1 or TAZ is significantly higher in GC tumor tissues than normal and significantly positively correlated (R=0.56, P =0.004) in GSE33335 cohort (** P <0.01; **** P <0.001); E . Expression of YAP1 or TAZ was determined using immunohistochemistry in 390 cases of GC specimen in both intestinal GC and diffuse GC. F . The correlation of YAP1 and TAZ in GC tissues was further confirmed in an individual GC cohort (GSE237876) (R=0.34, P =0.034). G. co-localization of YAP1 and TAZ in two representative PDXs GC tissues was determined by co-immunofluorescent staining of YAP1, TAZ and DAPI (scale bar: 25μm).

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: YAP1 and TAZ are highly expressed in GC tumor tissues and PDXs. A. Increased expression of YAP1 or TAZ (WWTR1) in GC tumor tissues compared to normal tissues from a public GC data set (GSE146996). B. Both YAP1 and TAZ are correlated (R=0.19) in the same dataset. C. Expression of YAP1 and TAZ in our own TMA of 390 GC Cases TAZ was statistically analyzed (p=0.001); D. co-expression of YAP1/EpCAM or TAZ/EpCAM was determined by co-IF in two representative PDXs; E. mRNA expression of YAP1 or TAZ was determined in tumor tissues of 18 PDXs from gastroesophageal cancers.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: A . expression of YAP1 and TAZ in tumor cell clusters was shown in dotted plots in 20 GCPM samples by scRNAseq. B. Coexpression of YAP1 and TAZ in 13 tumor cell clusters was shown in tSNE plots in GCPM samples by scRNAseq C . Expression of YAP1 and TAZ as determined by dual-immunofluorescent staining (co-IF) in representative GCPM samples. Scale bar: 10μm. D . High correlation of YAP1 and TAZ in two metastatic GC cohorts (GSE237876 and GSE289037). E. Expression of YAP1 was significantly increased in peritoneal metastasis compared to primary tumors from a GC cohort (GSE237876).

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, Staining

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: Co-expression of YAP1 and TAZ in representative GCPM samples. A. coexpression of YAP1 or TAZ in nuclear of two representative GCPM specimen was determined by co-IF staining; B. Coexpression of YAP1 with epithelial tumor marker EpCAM or TAZ or stromal marker vimentin and M2 macrophage marker CD163 in GA0518 GCPM cases; C. TAZ expression was determined in GC with peritoneal metastases compared to GC without peritoneal metastases from a public GC dataset GSE289037.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, Staining, Marker

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: A . scRNAseq showed the expression of TEAD1, TEAD2, TEAD3 and TEAD4 by dot plots from 20 GCPM specimens; B . Association of TEAD1-TEAD4 expression with GC patients’ survival in more than 600 advanced GC patients respectively from the TCGA database ( kmplot.com ). C . Representative GCPM cases stained by dual-immunofluorescence of YAP1 with TEAD1-TEAD4 respectively. D . YAP1 interacts with TAZ and TEAD1-TEAD4 in AGS and GA0518 GC cells as shown by co-immunoprecipitation pulldown using anti-YAP1 antibody. E . TAZ interacts with YAP1 and TEAD1-TEAD4 as shown by co-immunoprecipitation pulldown using anti-TAZ antibody in AGS and GA0518 GC cells. F . TEAD transcriptional activity was determined as previously by transient cotransfection of 5X UAS-luciferase reporter and Gal4-TEAD4 with either YAP1cDNA or TAZ cDNA or both in GA0518, GA0804 and AGS cells for 48 hours. *p<0.05, **p<0.01; ***p<0.001.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, Staining, Immunofluorescence, Immunoprecipitation, Activity Assay, Cotransfection, Luciferase

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: Antisense oligonucleotides (ASO) of YAP specifically suppress YAP expression, transcription, and reduce tumor cell malignant behaviors in vitro . A.YAP1 protein was determined by Western blot after treatment with YAP1 ASOs in GA0518 cells as indicated; B. YAP1 mRNA (left) and its target Cyr61 (right) mRNA levels were dose-dependently decreased by YAP1 ASO as determined by q-PCR in GA0518 cells **p<0.01; ***p<0.001; C . YAP1 protein was determined by Western blot after treatment with YAP1 ASOs in GA0804 cells; D. YAP1 mRNA (left) and its target Cyr61 (right) mRNA levels were decreased by YAP1 ASO as determined by q-PCR in GA0804 cells; **p<0.01; ***p<0.001; E . YAP1 ASO significantly inhibited tumor cell invasion in both GA0518 (left) and GA0804 (right) GCPM tumor cells. Lower panels, quantification. **p<0.01; ***p<0.001; F . Western blot showing YAP1 knockout efficiency (left); cell survival was detected by MTS assay in GA0518 cells with or without YAP1 KO (right) treated with YAP1 ASO at different dosage. *p<0.05; **p<0.01;

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, In Vitro, Western Blot, Knock-Out, MTS Assay

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: TAZ ASO suppresses TAZ expression, transcription, TAZ/TEAD transcriptional activity and reduces tumor cell invasion in vitro . A&B. TAZ protein and mRNA levels were decreased by TAZ ASO as determined by Western blot and q-PCR in both GA0518 and GA0804 cells; *p<0.05, **p<0.01; C . TAZ/TEAD transcriptional activity was determined as previously by transient cotransfection of 5X UAS-luciferase reporter and Gal4-TEAD4 with either TAZ cDNA or YAP1cDNA in GA0518 and GA0804 for 48 hours. *p<0.05, **p<0.01; ****p<0.001. D . Luciferase activity of YAP1/TAZ/TEAD was determined after cotransfection of 5X UAS-luciferase reporter and Gal4-TEAD4 with both TAZ cDNA and YAP1cDNA and then treated with YAP1 ASO or TAZ ASO in GA0518 cells; ****p<0.001; E . Luciferase activity of TAZ/TEAD was determined after cotransfection of 5X UAS-luciferase reporter and Gal4-TEAD4 with TAZ cDNA overexpression as done previously. ***p<0.001; F . TAZ ASO strongly suppressed tumor cell invasion capacity in a dose-dependent manner in both GA0518 (left) and GA0804 (right) cells. **p<0.01; ***p<0.001.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, Activity Assay, In Vitro, Western Blot, Cotransfection, Luciferase, Over Expression

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: TAZ ASO specifically suppress TAZ expression and inhibit GA0518 cell colony formation. A. Expression of YAP1 and TAZ was determined in GA0518 cells by western blot after treatment of TAZ ASO in dosage as indicated; B&C. Demonstration of colony formation (B) and quantification (C) in GA0518 cells treated with YAP1 ASO, TAZ ASO or a reported YAP1/TEAD inhibitor CA3 at the dosage indicated; *p<0.05, **p<0.01; ***p<0.001.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Expressing, Western Blot

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: A. TAZ level increased upon YAP1 KO by Western blot (left) and q-PCR (right) in GA0518 cells; B. YAP1 ASO decreased YAP1 but increased TAZ protein (left) and mRNA (right) levels in both GA0518 (above) and GA0804 (below) cells by Western blot and q-PCR respectively; C . YAP1 KO dramatically increased TAZ binding to TEAD4 and the AP1 heterodimer of C-JUN and FOSB as determined by co-IP in GA0518 cells; D . Similarly, inhibition of YAP1 by ASO increased TAZ binding to TEAD4 and the AP1 heterodimer of C-JUN and FOSB as determined by co-IP in GA0518 cells. E . Co-IF staining of TAZ and TEAD4 in four representative GCPM specimen. Scale bar: 25μm. F . Expression of YAP1, TEAD4, c-JUN and FOS-B was determined by co-IF using their specific antibody respectively in GA0518 YAP1 KO clones compared to GA0518 Control cells. Scale bar: 20μm.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Western Blot, Binding Assay, Co-Immunoprecipitation Assay, Inhibition, Staining, Expressing, Clone Assay, Control

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: A-D. YAP1 and TAZ protein and mRNA levels were determined by western blot and q-PCR upon treatment of YAP1 ASO or TAZ ASO or their combination in both GA0518 and GA0804 cells. *p<0.05, **p<0.01; ***p<0.001. E. Invasion capacity was determined by western blot and q-PCR upon treatment of YAP1 ASO or TAZ ASO or their combination in both GA0518 and GA0804 cells. **p<0.01; ***p<0.001; Scale bar: 25μm; F . Colony formation was determined in GA0804 cells upon treatment of YAP1 ASO or TAZ ASO or their combination. **p<0.01; ***p<0.001.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Western Blot

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: ASO co-targeting of YAP and TAZ significantly attenuated tumor growth in PDX with greater antitumor effects when combined with anti-PD1 immunotherapy in the KP-Luc syngeneic model. A-B. Combined ASO inhibition of YAP1 and TAZ suppressed tumor weights and volumes in the GA0518 PDX model; YAP1 ASO or TAZ ASO: 50mg/kg, 5 times a week for three weeks. C . Expression of YAP1, TAZ and KI67 as determined by IF staining or immunohistochemistry in YAP1, TAZ, or combination ASO-treated PDX tumors; Scale bar: 20 μm; D. Combination of YAP1 ASO and anti-PD1 antibody had greater antitumor effects than YAP1 ASO alone or the control group; *p<0.05, ***p<0.001; E . Expressions of YAP1, KI67 and SOX9 were decreased by the YAP1 ASO/anti-PD1 combination treatment, while CD8 infiltration was also increased by the combination treatment over either alone. Scale bar: 20 μm; F . Working model and the rationale for co-targeting YAP1 and TAZ in advanced GCPM patients.

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Inhibition, Expressing, Staining, Immunohistochemistry, Control

Journal: bioRxiv

Article Title: YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases

doi: 10.1101/2025.11.13.683933

Figure Lengend Snippet: ASO co-targeting of YAP and TAZ significantly attenuated tumor growth in additional PDX. A. Combined ASO inhibition of YAP1 and TAZ suppressed tumor weights in a GC PDX model; YAP1 ASO or TAZ ASO: 50mg/kg, the combination of YAP1 ASO (25mg/kg) and TAZ ASO (25mg/kg); 5 times a week for three weeks. B. Actually tumor sizes in different treatment groups were shown at the end of the experiment. C. co-expression of TAZ/vimentin and YAP1/EpCAM as determined by IF staining in YAP1 ASO, TAZ ASO, or combination ASO-treated PDX tumors; Scale bar: 20 μm;

Article Snippet: Sections were incubated with primary antibodies: human YAP1 antibody (Cell signaling, cat#14074; 1:100) and human TAZ antibody (Novus, cat#NBP1-85067; 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP kit (Vector Laboratories, PK-6100).

Techniques: Inhibition, Expressing, Staining